Premium
Syntheses of Platinum–Sulindac Complexes and Their Nanoparticles as Targeted Anticancer Drugs
Author(s) -
Hwu Jih Ru,
Tsay ShwuChen,
Chuang Kao Shu,
Kapoor Mohit,
Lin Jia Yu,
Yeh ChenSheng,
Su WuChou,
Wu PingChing,
Tsai TsungLin,
Wang PeiWen,
Shieh DarBin
Publication year - 2016
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201504915
Subject(s) - sulindac , chemistry , plga , glycolic acid , platinum , ic50 , pharmacology , stereochemistry , biochemistry , lactic acid , in vitro , medicine , biology , nonsteroidal , bacteria , genetics , catalysis
Platinum(II)–sulindac complexes [{η 2 ‐C 5 H 4 SN(O)}Pt(DMSO){O(C=O)Sulindac}], [{η 2 ‐C 5 H 4 SN(O)}PtCl{(S=O)Sulindac}], [{η 2 ‐C 5 H 4 SN(O)}PtCl{(S=O)Sulindac–succinimide}], and [{η 2 ‐C 5 H 4 SN(O)}PtCl{(S=O)Sulindac–thymidine}] were synthesized that exhibited IC 50 values of 2.9–4.8 μ m against human oral cancer cells OECM1. The poly(lactic‐ co ‐glycolic acid) (PLGA) encapsulated [{η 2 ‐C 5 H 4 SN(O)}PtCl{(S=O)Sulindac}] also showed cytotoxic activity although less potent than the pristine species.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom